The 14 most recent market catalysts affecting $ZBH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 60
Stifel Raises Price Target for Zimmer Biomet Holdings, Inc.
Stifel, a well-known financial firm, has raised its price target for Zimmer Biomet Holdings (ZBH) from $125 to $140. This upward revision indicates that Stifel analysts have a more…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Adjusts Price Target on Zimmer Biomet Holdings to $110 From $97
Leerink Partners has updated its valuation for Zimmer Biomet Holdings, raising the price target from $97 to $110. This adjustment indicates a more favorable outlook from the analys…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 55
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery
Zimmer Biomet announced a new technology category, 'Surgeon-Guided Autonomy,' at a key industry event, signaling its strategic focus on intelligent orthopedic surgery. This move is…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 55
Rothschild & Co Redburn Adjusts Price Target on Zimmer Biomet to $123 From $117
Rothschild & Co Redburn has revised its price target for Zimmer Biomet Holdings, Inc. upwards from $117 to $123. This change indicates a more optimistic outlook from the analyst fi…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Adjusts Price Target on Zimmer Biomet to $114 From $106, Maintains Hold Rating
Truist Securities adjusted its price target for Zimmer Biomet Holdings (ZBH) from $106 to $114, indicating a revised valuation of the company. Despite the increased price target, t…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Adjust Price Targets for Zimmer Biomet Following Third Quarter 2026 Earnings
This filing discloses that multiple investment firms have raised their price targets for Zimmer Biomet (ZBH) after the company's third-quarter 2026 earnings report. This is a posit…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 85
Zimmer Biomet Reports Third Quarter 2026 Financial Results
Zimmer Biomet announced its Q3 2026 financial results, reporting a 3.1% increase in net sales and maintaining adjusted diluted EPS year-over-year. The company highlighted strong pe…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 55
Zimmer Biomet Expands Its Distribution, Supply Deal With THINK Surgical To Continue Distribution Of THINK's Wireless TMINI Miniature Robotic System
Zimmer Biomet (ZBH) announced a multi-year extension of its limited exclusive distribution and supply agreement with THINK Surgical for the TMINI Miniature Robotic System. This ren…
Oct 7, 2026
Corporate Catalyst
Neutral
Impact 55
Barclays Initiates Coverage On Zimmer Biomet Holdings with Equal-Weight Rating, Announces Price Target of $100
Barclays analyst Christopher Pasquale initiated coverage on Zimmer Biomet Holdings (ZBH) with an 'Equal-Weight' rating and a $100 price target. This event is a routine part of anal…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Raises Price Target to $110
RBC Capital's analyst Shagun Singh maintained an 'Outperform' rating on Zimmer Biomet Holdings (ZBH) and raised the price target from $101 to $110. This action signals continued co…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Zimmer Biomet Holdings shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
This headline represents a significant corporate catalyst for Zimmer Biomet. Better-than-expected earnings and raised guidance are strong indicators of fundamental strength and imp…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Zimmer Biomet Holdings Q2 Adj. EPS $2.07 Beats $2.01 Estimate, Sales $2.177B Beat $2.134B Estimate
Zimmer Biomet Holdings (ZBH) announced Q2 adjusted EPS of $2.07, surpassing the analyst consensus of $2.01, and sales of $2.177 billion, exceeding the $2.134 billion estimate. This…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 75
Live On CNBC, Sarat Sethi Announces Sold Zimmer Biomet
Sarat Sethi, a well-known analyst, publicly announcing the sale of Zimmer Biomet (ZBH) on CNBC is a significant event for the company and its investors. This could signal a loss of…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.